Iqymune

Human Normal Immunoglobulin, the active ingredient in Iqymune, is an immunoglobulin presented as a sterile solution for intravenous use. It supplies pooled IgG antibodies to provide passive immunity and modulate immune responses in patients with antibody deficiencies.

GNH USA supplies Iqymune as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Iqymune is an intravenous immunoglobulin used to replace deficient antibodies and modulate immune activity in several clinical conditions. - Primary immunodeficiency diseases: restores IgG levels to reduce infection frequency. - Secondary immunodeficiency (e.g., after chemotherapy): provides passive immunity to protect against opportunistic infections. - Immune thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑antibody activity. - Kawasaki disease: reduces coronary artery inflammation and fever in acute phases.

Common Side Effects: - Headache: mild to moderate, often transient. - Fever and chills: typical infusion‑related reactions. - Nausea or vomiting: may occur during or shortly after infusion. - Fatigue: general tiredness reported by some patients. - Infusion site reactions: redness, swelling, or discomfort. - Aseptic meningitis: rare, presenting with headache and neck stiffness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: risk of clot formation, especially in high‑risk patients. - Acute renal failure: possible with high‑dose or rapid infusion. - Hemolysis: destruction of red blood cells leading to anemia. - Severe thrombocytopenia: markedly low platelet counts. - Aseptic meningitis: severe headache with meningeal signs.

Before initiating therapy, consider the following precautions. - Assess IgG levels: determine baseline immunoglobulin status. - Monitor renal function: check creatinine and urine output regularly. - Screen for IgA deficiency: patients with anti‑IgA antibodies may have severe reactions. - Observe for infusion reactions: start at a slow rate and watch for symptoms. - Avoid in patients with known severe IgA deficiency: risk of anaphylaxis. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

IvIG can interact with other medicines; monitor patients accordingly. Major Interactions (Avoid): - Live vaccines: may reduce vaccine efficacy and increase infection risk. - Anticoagulants (e.g., warfarin): increased risk of thrombosis. - High‑dose steroids: may exacerbate hyperviscosity. Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., rituximab): may alter immune response. - ACE inhibitors: potential for renal impairment. - Diuretics: monitor fluid balance and renal function.